Notice of Closed Meeting, 11085 [2020-03832]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 38 / Wednesday, February 26, 2020 / Notices
khammond on DSKJM1Z7X2PROD with NOTICES
Please note that comments received,
including attachments and other
supporting materials, are part of the
public record and are subject to public
disclosure. Comments will be posted on
https://www.regulations.gov. Therefore,
do not include any information in your
comment or supporting materials that
you consider confidential or
inappropriate for public disclosure. If
you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be on
public display. CDC will review all
submissions and may choose to redact,
or withhold, submissions containing
private or proprietary information such
as Social Security numbers, medical
information, inappropriate language, or
duplicate/near duplicate examples of a
mass-mail campaign. CDC will carefully
consider all comments submitted in
preparation of the final Infection Control
in Healthcare Personnel: Epidemiology
and Control of Selected Infections
Transmitted Among Healthcare
Personnel and Patients and may revise
the final document as appropriate.
Background
The Draft Guideline, located in the
‘‘Supporting & Related Material’’ tab of
the docket, updates four sections of the
1998 Guideline, Part E: Epidemiology
and Control of Selected Infections
Transmitted Among Health Care
Personnel and Patients, and their
corresponding recommendations in Part
II of the 1998 Guideline: ‘‘4.
Diphtheria;’’ ‘‘9. Meningococcal
Disease;’’ ‘‘12. Pertussis;’’ and ‘‘18.
Streptococcus, group A infection.’’ That
section provided information and
recommendations for Occupational
Health Services (OHS) of healthcare
facilities and systems on the prevention
of transmission of infectious diseases
among healthcare personnel (HCP) and
patients. Additional updated sections
are forthcoming.
The Draft Guideline is intended for
use by the leaders and staff of OHS to
guide the management of exposed or
infected HCP who may be contagious to
others in the workplace. The draft
recommendations update the 1998
recommendations with current guidance
on the management of exposed or
potentially infectious HCP, focusing on
postexposure management, including
postexposure prophylaxis (PEP), for
exposed HCP and work restrictions for
exposed or infected HCP.
Since 2015, the Healthcare Infection
Control Practices Advisory Committee
(HICPAC) has worked with national
partners, academicians, public health
professionals, healthcare providers, and
VerDate Sep<11>2014
17:22 Feb 25, 2020
Jkt 250001
other partners to develop this Draft
Guideline as a recommendation for CDC
to update sections of the 1998
Guideline. HICPAC includes
representatives from public health,
infectious diseases, regulatory and other
federal agencies, professional societies,
and other stakeholders.
The updated draft recommendations
in this Draft Guideline are informed by
reviews of the 1998 Guideline; current
CDC resources, guidance, and
guidelines; and new resources and
evidence, when available. This Draft
Guideline will not be a federal rule or
regulation.
Dated: February 21, 2020.
Sandra Cashman,
Executive Secretary, Centers for Disease
Control and Prevention.
11085
For Further Information Contact:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road, NE, Mailstop US8–1,
Atlanta, Georgia 30329, (404) 718–8833,
gca5@cdc.gov.
The Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease
Control and Prevention, has been
delegated the authority to sign Federal
Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
[FR Doc. 2020–03848 Filed 2–25–20; 8:45 am]
Kalwant Smagh,
Director, Strategic Business Initiatives Unit,
Office of the Chief Operating Officer, Centers
for Disease Control and Prevention.
BILLING CODE 4163–18–P
[FR Doc. 2020–03832 Filed 2–25–20; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Notice of Closed Meeting
Frm 00041
Fmt 4703
Sfmt 4703
Centers for Disease Control and
Prevention
[Docket No. CDC–2020–0001; NIOSH–333]
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Director, Strategic Business
Initiatives Unit, Office of the Chief
Operating Officer, CDC, pursuant to
Public Law 92–463. The grant
applications and the discussions could
disclose confidential trade secrets or
commercial property such as patentable
material, and personal information
concerning individuals associated with
the grant applications, the disclosure of
which would constitute a clearly
unwarranted invasion of personal
privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–PS–20–001, Evaluation of New HIV
Testing Technologies in Clinical
Settings with High HIV Incidence.
Date: June 9, 2020
Time: 10:00 a.m.–5:00 p.m., (EDT)
Place: Teleconference, Centers for
Disease Control and Prevention, Room
1080, 8 Corporate Square Blvd., Atlanta,
GA 30329.
Agenda: To review and evaluate grant
applications.
PO 00000
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Developing a Workplace Supported
Recovery Program: A Strategy for
Assisting Workers and Employers With
the Nation’s Opioid and Substance Use
Disorder Epidemics: Request for
Information
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Request for information.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH), within the Centers for Disease
Control and Prevention (CDC),
announces an opportunity to provide
input on a NIOSH plan to develop
resources and conduct research on the
topic of Workplace Supported Recovery.
Workplace Supported Recovery
programs (WSRPs) assist workers and
employers facing the nation’s crisis
related to the misuse of opioids and
other drugs, and related substance use
disorders.
DATES: Comments must be received
April 27, 2020.
ADDRESSES: You may submit written
comments, identified by docket
numbers CDC–2020–0001 and NIOSH–
333, by either of the following two
methods:
SUMMARY:
E:\FR\FM\26FEN1.SGM
26FEN1
]]>Agencies
[Federal Register Volume 85, Number 38 (Wednesday, February 26, 2020)]
[Notices]
[Page 11085]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-03832]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Director, Strategic
Business Initiatives Unit, Office of the Chief Operating Officer, CDC,
pursuant to Public Law 92-463. The grant applications and the
discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--RFA-PS-20-001, Evaluation of New
HIV Testing Technologies in Clinical Settings with High HIV Incidence.
Date: June 9, 2020
Time: 10:00 a.m.-5:00 p.m., (EDT)
Place: Teleconference, Centers for Disease Control and Prevention,
Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.
Agenda: To review and evaluate grant applications.
For Further Information Contact: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road, NE, Mailstop US8-1,
Atlanta, Georgia 30329, (404) 718-8833, [email protected].
The Director, Strategic Business Initiatives Unit, Office of the
Chief Operating Officer, Centers for Disease Control and Prevention,
has been delegated the authority to sign Federal Register notices
pertaining to announcements of meetings and other committee management
activities, for both the Centers for Disease Control and Prevention and
the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-03832 Filed 2-25-20; 8:45 am]
BILLING CODE 4163-18-P
